65,437 trials
Enterocolitis Clostridium Difficile Recurrent
Primary: Treatment Success of Group A (2 Doses of RBX2660) vs Group B (2 Doses of Placebo) (ITT) — 25; 19; 20; 25 Participants
Autosomal Dominant Polycystic Kidney Disease
Primary: Total Kidney Volume — 1428; 1675; 1728; 1775 mL
Prostate Cancer
Primary: Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12 — 47; 89; 88; 22…
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Epilepsy · Lennox-Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -43.90; -21.80 percentage change — p=0.0135
Metastatic ER+ Her2- Breast Cancer · Postmenopausal
Primary: Progression-Free Survival (PFS) — 3.68; 3.65; 4.47 Months — p=0.437
Cystic Fibrosis
Primary: Absolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28 — -0.5; -0.9 percentage of whole-lung clearance — p=0.7151
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) — 0.8; 3.8; 2.3; 4.4 percent change — p=< 0.001
Epilepsy · Lennox Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -41.86; -37.16; -17.17 percentage change — p=0.0047
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
Nausea · Vomiting
Primary: Complete Response Rates Among Standard of Care and Combination Therapy Groups. — 58; 73; 31; 17 Participants — p=<.001
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants
Tetralogy of Fallot (TOF) · Ventricular Septal Defects (VSD) · Atrioventricular Septal Defects (AVSD)
Primary: ACTH and Cytokine Levels — 116.9; 182.7; 135.3; 44.5 pg/mL
Influenza
Primary: Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever — 120; 11 Participants
Single Edentulous Space
Primary: Number of Participants With Abutment Margin Exposure > 0 — 0; 0 Participants — p=1.00